Literature DB >> 15647233

States' allocations of funds from the tobacco master settlement agreement.

Frank A Sloan1, Jennifer S Allsbrook, Leanne K Madre, Leah E Masselink, Carrie A Mathews.   

Abstract

This study assesses six states' allocation decisions for funds from tobacco settlement agreements, using information from newspaper articles and other public sources. State allocation decisions were diverse; substantial shares were allocated to areas other than tobacco control and health, including capital projects and budget shortfalls. The allocations did not reflect the stated goals of the lawsuits leading to the settlements. This outcome reflects a lack of strong advocacy from public health interest groups, an unreliable public constituency for tobacco control, and inconsistent support from state executive and legislative branches, all combined with sizable budget deficits that provided competing uses for settlement funds.

Entities:  

Mesh:

Year:  2005        PMID: 15647233     DOI: 10.1377/hlthaff.24.1.220

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  4 in total

1.  Funding of North Carolina tobacco control programs through the Master Settlement Agreement.

Authors:  Alison Snow Jones; W David Austin; Robert H Beach; David G Altman
Journal:  Am J Public Health       Date:  2006-11-30       Impact factor: 9.308

Review 2.  The Master Settlement Agreement and its impact on tobacco use 10 years later: lessons for physicians about health policy making.

Authors:  Walter J Jones; Gerard A Silvestri
Journal:  Chest       Date:  2010-03       Impact factor: 9.410

3.  Master Settlement Agreement (MSA) spending and tobacco control efforts.

Authors:  Jayani Jayawardhana; W David Bradford; Walter Jones; Paul J Nietert; Gerard Silvestri
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

4.  Effective tobacco control in Washington State: a smart investment for healthy futures.

Authors:  Julia Dilley; Kristen Rohde; Clyde Dent; Michael J Boysun; Michael J Stark; Terry Reid
Journal:  Prev Chronic Dis       Date:  2007-06-15       Impact factor: 2.830

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.